Connect Biopharma Holdings Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $139.8M
- Price
- $2.51
- % Change (Daily % change from the live per-ticker quote feed.)
- +13.04%
- Volume
- 672.3K
Quote data as of 7:03 AM ET
About
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Quick stats
Shares outstanding63.0M
Computed float56.5M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001835268
AI Summary
AI-generated22d agostandardbullishclinical trialConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Connect Biopharma completed enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart, with topline data expected in early September 2026.
The company is also on track to complete enrollment in the corresponding Phase 2 Seabreeze STAT COPD study this month, with both trials targeting acute exacerbations in 160 participants each.
Management highlighted a strong balance sheet providing a cash runway into the second half of 2027, alongside eligibility for up to $110 million in remaining milestones from partner Simcere.